F
Foundry BioSciences
Biotech & Life Sciences · Boston, United States · Founded 2025
Protein engineering with AI to extend longevity and elevate quality of life MoreLess
Foundry BioSciences is a biotechnology firm focused on extending human healthspan through the application of artificial intelligence in protein engineering. The company was co-founded by CEO Jingjing Chai and Kaiyi Jiang. Jingjing Chai is a Harvard alumnus with a decade of experience in deep-tech venture investments and technology transfer. Co-founder Kaiyi Jiang holds a PhD from MIT, was an inaugural Amgen Science Fellow, and is recognized in MIT Technology Review Asia's "35 Under 35". Their collective expertise in investment and life sciences forms the foundation of the company's strategy.
The core of Foundry BioSciences' operation is its AI-driven Protein Evolution Engine, which leverages protein language models and experimental validation to design and optimize proteins. This platform aims to address the molecular challenges of aging, such as cellular damage, protein dysfunction, and a weakening immune system. The company's technology is engineered to accelerate the discovery process, reducing protein engineering timelines from years to months. A key feature is the ability to generate proteins with significantly improved activity—reportedly 10 to 100 times greater than their natural counterparts.
The business model centers on providing computational services and developing healthspan-enhancing products. By creating proteins with superior properties, the firm targets the longevity and healthspan markets. The company's process involves iterative refinement guided by performance data and continuous improvements driven by experimental feedback cycles, a method designed to precisely address specific mechanisms of aging. This approach allows for the targeted design of proteins to combat age-related conditions.
Keywords: protein engineering, artificial intelligence, longevity, healthspan, biotechnology, AI-driven drug discovery, protein language models, computational biology, age-related diseases, cellular aging, protein optimization, enzyme engineering, metabolic decline, immunosenescence, therapeutic proteins, life sciences, deep tech
Company overview
Foundry BioSciences company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2025
- Headquarters
- Boston, United States
- Employees
- 4
- Open positions
- None listed
- Dealroom signal
- 79.3
Valuation & funding
Foundry BioSciences funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Jul 2025 | $20M | $80M | Yael Capital Management · Taihill Venture · XtalPi | ↗ |
| SPINOUT✓Other financing | Jan 2025 | $0 | — | Massachusetts Institute of Technology | — |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 4 |
| 2025 | 3 |
Growth signals
Foundry BioSciences website traffic
Latest recorded traffic for Foundry BioSciences is 1.4K monthly website visits, up 77.2% over the last three months. Foundry BioSciences's team grew 33.3% over the past year.
Comparisons
Foundry BioSciences compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Foundry BioSciences's talent
Source: Dealroom Talent Intelligence.
Investors
4 investors on Foundry BioSciences's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Foundry BioSciences has talent and traffic
team presence
In the news
Latest news about Foundry BioSciences
Recent press, funding announcements, and product moves mentioning Foundry BioSciences — open to read from the original sources.
Market sentiment
What the market is saying about Foundry BioSciences
An AI-synthesized read of the highest-engagement posts about Foundry BioSciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Foundry BioSciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.